

ABSTRACT OF THE DISCLOSURE

[00083] The invention relates to uses of kappa-conotoxin PVIIA ( $\kappa$ -PVIIA), analogs and derivatives for activating ATP-sensitive  $K^+$  channels. The activation of ATP-sensitive  $K^+$  channels is useful for opening  $K_{ATP}$  channels which can be used to treat a wide range of disease and injury states, including cerebral and cardiac ischemia and asthma.